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Objectives: This study describes the health technology assessment (HTA) framework introduced by Regione Lombardia to regulate the introduction of new technologies. The study
outlines the process and dimensions adopted to prioritize, assess and appraise the requests of new technologies.
Methods: The HTA framework incorporates and adapts elements from the EUnetHTA Core Model and the EVIDEM framework. It includes dimensions, topics, and issues provided by
EUnetHTA Core Model to collect data and process the assessment. Decision making is instead supported by the criteria and Multi-Criteria Decision Analysis technique from the EVIDEM
consortium.
Results: The HTA framework moves along three process stages: (i) prioritization of requests, (ii) assessment of prioritized technology, (iii) appraisal of technology in support of
decision making. Requests received by Regione Lombardia are first prioritized according to their relevance along eight dimensions (e.g., costs, efficiency and efficacy, organizational
impact, safety). Evidence about the impacts of the prioritized technologies is then collected following the issues and topics provided by EUnetHTA Core Model. Finally, the
Multi-Criteria Decision Analysis technique is used to appraise the novel technology and support Regione Lombardia decision making.
Conclusions: The VTS (Valutazione delle Tecnologie Sanitarie) framework has been successfully implemented at the end of 2011. From its inception, twenty-six technologies have
been processed.
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The present study describes the health technology assessment
(HTA) framework implemented in 2008 by Regione Lombardia
(RL) to decide on the introduction and delisting of health tech-
nologies. The framework (named VTS, Valutazione delle Tec-
nologie Sanitarie) applies the EUnetHTA Core Model R© (1;2)
to define the procedures, responsibilities, and criteria that the
Health General Directorate follows for evidence-based and le-
gitimate decisions.
The introduction of a formalHTA framework stemmed from
a strive to balance goals of continuous innovation with needs of
steady cost containments. While introducing state-of-art tech-
nologies is crucial for higher standards of care, their expen-
ditures are critical factors for the increase of healthcare costs
(3–5). Policy makers have thus emphasized the introduction of
tools that manage which, why, and how technologies get in or
out the system (6).
RL targeted these concerns by using the EUnetHTA Core
Model to legitimize a structured approach in the adoption and
delisting of technologies. Specifically, the Core Model is not
used as a generic guideline for HTA, but formalized in three re-
gional laws that compelRL into following a standard procedure.
The Core Model in the VTS framework supports the en-
tire decision-making process of RL, i.e. prioritizing technol-
ogy requests; assessing the impacts of the technology; apprais-
ing the decision to invest in the technology (6). Two changes
were introduced to fulfill this purpose. First, the framework
makes explicit the implementation of a cost-opportunity logic
according to which the adoption of new technologies must be
balanced by the delisting of obsolete ones. Second, the frame-
work incorporates tools and techniques for Multi-Criteria De-
cision Analysis (MCDA) (7). The Core Model concentrates
on data collection and technology assessment, but does not
endorse explicit tools to translate the latter into decisions.
MCDA served this purpose, and its inclusion required a few
changes to the Core Model, that is, (i) map EUnetHTA do-
mains into dimensions that RL set up to legitimize the priori-
tization of technologies and (ii) include criteria from an open
source framework (EVIDEM) that could best support the sys-
tematic appraisal of the assessment report into a final deci-
sion (7). Both “dimensions” and “criteria” are consistent with
the Core Model as they do not distort its logic, structure, and
contents.
The present study will describe the VTS framework in all
its components. The study is structured as follows. In section
one, we outline the context of RL, in which the framework takes
place. Then, we describe the key principle of cost-opportunity
that grounds the framework. Next, we outline the elements com-
posing the VTS architecture, and the process of its functioning.
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Last, we discuss current experiences with framework imple-
mentation.
CONTEXT OF APPLICATION
Under the Italian Constitution, the primary responsibility for
Healthcare is granted to Regions, which are autonomous in
the organization of services and can independently choose the
nature and quantity of technological investments (8). The re-
gional nature of the Italian Healthcare System leads to the lack
of a national agency that could mandate and control the im-
plementation of a shared HTA framework. Responsibility to
assert HTA frameworks is delegated to each Region, with the
result of having twenty-one distinct HTA applications in Italy
(9).
RL represents one of the leading systems in terms of tech-
nology investments and quality of care. RL includes almost
10 million residents and 30,000 beds; and employs 150,000
healthcare professionals, 8,000 general practitioners. RL is
organized as a quasi-market system (8), with a neat distinc-
tion between purchasers (fifteen Local Health Authorities) and
providers (twenty-nine hospitals, four research institutes, and
almost 200 other healthcare organizations). Public healthcare-
related expenditures amass to 17,000 mil € in 2012, which
represent the vast majority of RL budget. The need to monitor
local expenditures on the budget triggered the formalization of
a HTA framework to decide over the introduction/delisting of
technologies.
COST-OPPORTUNITY AND THE VTS FRAMEWORK
The VTS framework aims at supporting the continuous refur-
bishment of technologies under the constraints of fixed budgets.
Such constraints magnify the role of opportunity costs associ-
ated with new investments, because the resources spent in a
new technology might prevent investments somewhere else. RL
conceived theVTS framework as a structured tool to identify ob-
solete technologies whose disinvestments could clear financial
space for new investments. The VTS framework is thus struc-
tured to provide knowledge on (i) the comprehensive improve-
ments associated with new technologies, vis-a`-vis established
ones; (ii) the possibility and extent of substituting obsolete tech-
nologies with the new ones.
Traditional cost-effectiveness analyses (CEA) fall short in
both regards. The attention on costs and effectiveness is signif-
icantly less informative for policy makers than HTA methods
that assume a multidimensional perspective. Also, CEA stimu-
late the accumulation, rather than the substitution, of technolo-
gies because they provide a rational for investment, but not for
disinvestment (10–12).
The VTS framework adopts instead a principle of cost-
opportunity which considers how new technologies substitute
established technologies and, thus, push disinvestments. The
VTS framework incorporates this principle by explicitly re-
quiring proponents of new technologies to indicate which set
of established technologies would become obsolete after the in-
vestment and, thus, candidates for disinvestment. This approach
is applied at its best when a new technology replaces established
ones. In this case, resources necessary to cover the new invest-
ment can be found from the disinvestment. The approach can
be also applied when the new technology does not replace,
but adds, to established ones. In this case, while no obsolete
technology is fully disinvested, it is still possible to identify ac-
tivities, processes, and resources that would become redundant
or unnecessary with the new technology. Removing them, it is
then possible to reduce the budget costs necessary for the new
investment.
ELEMENTS OF THE VTS FRAMEWORK
The cost-opportunity analysis is performed through a structured
model for (i) the collection and assessment of scientific evidence
about technology impacts and (ii) the appraisal of results in
ways that can be promptly communicated to and understood by
decision makers.
VTS Framework Combines EUnetHTA and EVIDEM Models for These Purposes
The EUnetHTA Core Model represents an important European
reference for technology assessment because it is the result of
joint work from multiple agencies (1). It delineates a nested
structure of issues, topics, and domains that organizes the col-
lection and assessment of evidence. At top level, the model out-
lines nine domains (Table 1). Each domain represents “a wide
framework within which technology is considered. It provides
an angle of viewing the use, consequences and implications
of technology” (EUnetHTA, 2011). Domains reflect the fact
that data for technology impacts should be managed by experts
in different disciplinary areas. Each domain is populated with
several topics, representing the specific areas in which differ-
ent impacts can be expected. For instance, the domain “clinical
effectiveness” includes topics such as mortality, morbidity, and
quality of life. Each topic includes several issues which rep-
resent the questions that experts should answer to assess tech-
nology impacts. For instance, to assess the impact on quality
of life, an expert should answer to issue D0012: “What is the
effect of the technology on health-related quality of life?” and
D0016: “How does the use of technology affect activities of
daily living?”
TheEUnetHTAModelwas adoptedwith two changes. First,
the nine EUnetHTA domains were re-elaborated into eight di-
mensions (cf. Table 1). The changes were made to discern
the impacts of the novel technology—while domains focus on
aspects of the technologies. The differences between the domain
“organizational aspects” and the dimension “organizational im-
pacts” (Table 1) can be illustrative. The domain includes is-
sues that originate from organizational aspects, but might exert
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Table 1. Comparison between EUnetHTA Domains and VTS Dimensions (with One Illustrative Example of Operationalization)
EUnetHTA domains VTS dimensions
1. Health problem and current use of technology
2. Technical characteristics of technology
3. Safety
4. Clinical effectiveness







5. Economic and financial impacts




Operationalization of Domain with EUnetHTA Issues:
G0001 - What kind of work flow and patient flow processes are needed?
G0002 - What kind of patient involvement in treatment or care has to be mobilized?
G0003 - What kind of staff, training and other human resources is required?
G0004 - What kind of cooperation and communication of activities have to be mobilized?
8. Organizational impacts
Operationalization of Dimension with EUnetHTA Issues:
G0001 - What kind of work flow and patient flow processes are needed?
G0002 - What kind of patient involvement in treatment or care has to be mobilized?
G0003 - What kind of staff, training and other human resources is required?
G0004 - What kind of cooperation and communication of activities have to be
mobilized?
G0005 – What consequences the new technology will have in respect of centralization?
G0006 – What kinds of investments are needed (material or premises)? These issues are included in the dimension “Economics and Financial Impacts”
G0007 – What is the budget impact of the implementation of the technology for the
payers?
G0008 - What management problems and opportunities are attached to the new
technology?
G0008 - What management problems and opportunities are attached to the new
technology?
G0009 - Who decides which patients are to undergo a treatment and on what basis? G0009 - Who decides which patients are to undergo a treatment and on what basis?
G0010 - How is the new technology accepted? These issues are included in the dimension “Social Impacts”
G0011 - How will other interest groups be taken into account in planning/implementation?
These issues are included in the domain “Safety” C0020 - What kind of occupational harms may exist using the technology?
C0040 - What kind of environmental risks may use of technology cause?
C0060 - How does the safety profile vary between different generations, versions,
products?
C0061 - Is there evidence that harms increase/decrease in different organizational
settings?
C0062 - How can one reduce safety risks for patients?
C0063 - How can one reduce safety risks for professionals?
C0064 - How can one reduce safety risks for environment?
impacts elsewhere. The issue G0006—that is, economic invest-
ments to guarantee viable organizational premises—ismoved in
the dimension “economic impacts” because it exerts an impact
on the costs spent for the technology.
Second, EVIDEM criteria are incorporated to support the
appraisal stage. The Core Model does not define a structured
approach to appraise the results of its assessment; EVIDEM
does so by implementing the MCDA approach. The appraisal
is structured in a set of criteria (cf. Table 2) which “reflect ex-
plicitly the thinking process underlying appraisal/prioritization
of healthcare interventions” (13). The MCDA approach repli-
cates decision-making process by: (i) considering together all
relevant criteria that intervene in the decision, (ii) assigning a
weight to each criteria that reflect how relevant that criterion
is for decisions, (iii) recognizing how strongly a new technol-
ogy makes improvement in each criterion. To our knowledge,
EVIDEM provides the most advanced and used definition of
criteria for appraisal (14;15), and was thus adopted as reference
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Size of population (D2)
General Healthcare Goals (T1)
Description of technology and benefits areas (T2)
Completeness and consistency of documentation (Q2)
Relevance and validity of documentation (Q3+Q1)
Disease impact
D1. Disease severity
D2. Size of population
Type of benefit
T1. Public health interest
T2. Type of medical service
Quality of evidence
Q1. Adherence to decision-making body
Q2. Completeness of reporting evidence
Q3. Relevance and validity of evidence
Safety
Improvement of Safety and Tolerability (I2)
Effectiveness and Efficacy
Improvement of Effectiveness and Efficacy (I1)
Improvement of patient related outcomes (I3)
Guidelines & good practice recommendations (C1)
Limitations of alternative technologies in use (C2)
Intervention outcomes
I1. Improvement of efficacy/ effectiveness
I2. Improvement of safety & tolerability
I3. Improvement of patient reported outcomes
Context of intervention
C1. Clinical guidelines
C2. Comparative interventions limitations
Economic and Financial Impact
Financial Impact on Health system (E1)
Cost-effectiveness (E2)
Impact on other spending (E3)
Impact on efficiency (cost-opportunity) (ET2)∗
Economics
E1. Budget impact on health plan
E2. Cost-effectiveness of intervention
E3. Impact on other spending
Equity
Impact on equity and accessibility (ET3)∗
Social and Ethical Impact D7
Coherence with national regional planning (ET1)∗
Impact on healthcare needs (ET1)∗
Pressure of interest groups (O2)∗
Historical and political context (O3)∗
Organizational Impact D8
System capacity, appropriate technology use (O1)∗
Et. Ethical framework
ET1. Goals of healthcare – utility
ET2. Opportunity costs – efficiency
ET3. Population priority & access – fairness
O. Other criteria
O1. System capacity, appropriate use of intervention
O2. Stakeholder pressures
O3. Political/historical context
Note. Asterisks indicate implicit criteria.
model. The VTS framework provides minor changes to EVI-
DEM criteria to maintain consistency with EUnetHTA issues
(cf. Table 2).
The changes respect the four properties required to apply
MCDA, that is, mutual independence, completeness, nonredun-
dancy, and operationalizability of criteria. In particular, criteria
are operationalized through EUnetHTA issues (cf. Table 3), and
independence and nonredundancy between criteria are guaran-
teed by imposing that an issues could be included in only one
criteria.
PROCESS OF VTS FRAMEWORK
The VTS framework is applied in a three-step process com-
prising (i) a prioritization of requests, grounded on a “quick
and dirty” assessment limited to VTS dimensions; (ii) a full as-
sessment of the prioritized technologies, provided by answering
EUnetHTA-based issues; (iii) an appraisal of the assessed tech-
nologies, grounded on the analysis of multiple criteria. Each
step is performed by a specific agent that is formally assigned
by RL after getting clearance over conflict of interest. Figure 1
provides an overview of VTS elements, process, and actors.
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Table 3. Illustrative Criteria in the VTS Framework
Criterion C7: Improvement of Safety and Tolerability
Topic: Mortality/Morbidity
1. What is the mortality and morbidity related to the diagnostic technology?
2. What is the mortality related to the technology studied?
Topic: Patient Safety
3. What are the consequences of false positive, false negative and incidental findings brought about using the technology to the patients from the viewpoint of patient safety?
4. What kind of harms can use of the technology cause to the patient and what is the incidence, severity and duration of harms?
5. What are the special features in using (applying/interpreting/maintaining) the technology that may increase the risk of patient safety?
6. What is the dose relatedness of the harms to patients?
7. What is the timing of onset of harms to patients: immediate, early or late?
8. Is the incidence of the harms to patients likely to change over time?
9. Are there susceptible patient groups more likely to be harmed through use of the technology?
10. What is the safety in comparison to alternative technologies used for the same purpose?
Figure 1. Actors, processes, and components of the VTS (Valutazione delle Tecnologie Sanitarie) framework.
STEP 1: PRIORITIZATION
RL receives every year a large amount of requests from dif-
ferent stakeholders about different types of new health tech-
nologies (drugs, devices, equipment supplies, procedures, and
organizational systems). The Regional Act 7856/2008 formal-
ized who can ask for the assessment, and how. Requests can
originate only from “accredited actors,” ranging from no profit
(i.e., care-giving organizations included in the Regional Health
Database, scientific and professional societies, patients associ-
ations, and universities) to for-profit organizations (i.e. phar-
maceutical, biotech, diagnostic firms). Proponents must fill a
form with information about: (i) their details, (ii) the current
technologies that will be considered as comparators and can-
didates for disinvestment, (iii) evidence on the impacts of the
new technology on the eight dimensions of the VTS framework.
Incomplete documentation will meet a desk-rejection. Appro-
priate requests are prioritized to identify which technologies
deserve full assessment and which should be assessed first.
Process of Prioritization. Requests are sent to the Regional Unit of Pri-
oritization and Conflict of Interests (NVPCI from the Italian
wording) which includes twenty-four members—three mem-
bers fromRegional Health Directorates; eight fromHospital Di-
rectorates; eight from Health Authority Directorates; five from
Care Scientific Centers. The members are formally appointed in
regional deliberations and serve for 3 years. Each prioritization
involves eight members—two members from each typology of
directorate.
The NVPCI gathers twice—at the beginning to define the
object of investigation and consolidate the comparators that
would be used as candidates for disinvestment and at the end to
deliver the prioritization decision. The stage lasts normally 45
days.Most of their work can be done online, through a dedicated
Web-platform. The NVPCI provides a first rapid assessment,
according to the eight dimensions (cf. Table 1).
The prioritization follows two steps. First, the NVPCI
checks the attached documentation and removes all requests
for new technologies which (i) cause a significant deterio-
ration in efficacy/effectiveness, (ii) endanger patient safety,
(iii) are irrelevant for healthcare purposes. Later, The NVPCI
applies a Multi-Dimension Decision Analysis (MDDA) which
takes the following form: Rank (technology j) = i=18 [weight
(dimension i) ∗ point (dimension i, technology j)]. Moving from
right to left in the equation, each health technology receives a
1–5 point for each of the eight dimension of the VTS frame-
work. The score defines to which extent the novel technol-
ogy improves the status quo in that particular dimension (i.e.,
109 INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 30:1, 2014
https://doi.org/10.1017/S0266462313000639
Downloaded from https:/www.cambridge.org/core. Open University Library, on 12 Feb 2017 at 08:51:41, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
Radaelli et al.
1 = high aggravation; 3 = no differential impact; 5 = high
improvement).
Each dimension has a weight that tells how relevant it is
compared with the other seven dimensions. The weight is elab-
orated by the NVPCI and is valid for any technology used
within a specific care pathway. Each member defines to which
extent the dimension was relevant for decision making, on a 1–8
scale (1 = irrelevant; 8 = essential). Individual ranks are then
gathered and elaborated to define for each dimension a relative
measure of importance (a weight).
The health technology under prioritization has specific
points for each dimensions (i.e., how enriching the technology
is for a specific dimension) and each dimension has a specific
weight (i.e., how relevant the dimension is for prioritization).
The product of these factors gives an overall rank that asserts
how relevant the technology is for prioritization. Technologies
can be then put in a ranking and divided into high, moder-
ate, and low priorities, and move forward to full assessment.
Technologies that have a rank <2 (i.e., low improvement) are
rejected.
The decision is then communicated to all interested
stakeholders—who are given: (i) an executive summary of the
prioritization, which explains the decision; (ii) an explanation of
the process followed to produce the prioritization decision; and
(iii) the weight, points, and comments of the NVPCI—with con-
tributors properly anonymized. Proponents of the technology
are given an opportunity to appeal against a rejection decision.
STEP 2: FULL ASSESSMENT
Health technologies that pass prioritization proceed to the “full
assessment” stage. Evidence about the multidimensional im-
pacts of the technology is systematically collected and pro-
cessed by a panel of experts identified by NVPCI. Specifically,
the NVPCI assigns experts to one of the eight dimensions of
the framework and have no conflicts of interest.
The panel gathers on average four times for each
assessment—at the beginning to gather initial information about
the goal of the assessment, typically two more times to discuss
critical issues in the assessment and at the end of a process to
consolidate the assessment. The process lasts on average 3/4
months.
Within the panel, one actor is appointed as the conductor and
given the responsibility to assign specific criteria to each expert
and synthesize their contributions. The panel of experts is re-
sponsible for elaborating knowledge on each of the twenty-one
criteria of the framework, by collecting evidence and answering
to the relevant issues in each criterion.
Review and Grading of Evidence
The starting point in full assessment is the systematic review
of scientific evidence. The experts are required to search for
contributions in databases of primary studies (e.g., MEDLINE,
Embase, CochraneControlledTrials Registry, Clinicaltrias.gov)
and of secondary studies (e.g., Cochrane Reviews Database,
Web sites of HTA Agencies (e.g., ANSM, CADTH, DHMA,
DIMDI, HAS, IQWIG, NICE, Osteba, etc.), specifying the re-
search strategy—that is, keywords and database queries—and
the criteria for inclusion and exclusion of contributions.
The resulting publications are registered according to the ty-
pology of study design—meta-analyses, randomized controlled
clinical trials, observational studies, etc. The classification is
the first step in the grading of evidence. Relevant included con-
tributions are graded on a 1–4 scale according to the degree
of scientific validity and applicability to Lombardy of their
findings. In practice, the panel of experts assesses the validity
and applicability of evidence using distinct assessment models
for: (i) epidemiological documentation; (ii) clinical outcomes;
(iii) economic/organizational documentation; (iv) budget im-
pact analysis.
Assessment of Impacts
The collected evidence is used to address the issues in each
criterion. As we observed, issues represent in fact the basic
questions that experts must address to inform the assessment.
The inclusion of issues in criteria and dimensions allows break-
ing down the technology assessment into smaller units that can
be assigned separately to field experts. All the answers to the is-
sues provided by the experts are included in a shared document,
called Multidimensional Impacts Form (MIF). The contents of
the MIF document are processed and later synthesized into
a comprehensive assessment of technology impacts. The MIF
represents the primary input of the next stage of appraisal.
STEP 3: APPRAISAL
The appraisal is performed by the Regional Technical
Roundtable for Medical Appropriateness (TTRAM from the
Italian wording). The TTRAM includes forty members selected
from curricula by the Regional Health Directorate; from Hospi-
tal Directorates; Health Authority Directorates; Care Scientific
Centers, Professional Associations and Universities. The mem-
bers are formally appointed in a regional deliberation and serve
for three years. Each appraisal “uses” twenty members.
The TTRAM gathers twice—at the beginning and at the
end of a process that normally lasts 45 days. Most of their
work can be done online, through aWeb-platform. The TTRAM
appraises the results from the assessment by using EVIDEM-
based criteria in the MCDA approach.
The appraisal follows two steps: (i) the definition of a quan-
titative score for fifteen explicit criteria, (ii) the definition of
qualitative comments for six implicit criteria. Consistently with
EVIDEM, in fact, the VTS framework distinguishes between
fifteen explicit and six implicit criteria (cf. Table 3).
Criteria are deemed explicit if they can be measured using
approach and indicators that are independent from the specific
technology, context of application or the time of decision. The
fifteen explicit criteria can thus be treated in a linear addictive
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equation, that is: Score (technology j)= k=18 [weight (explicit
criterion k) ∗ point (criterion k, technology j)].
Each explicit criterion is first weighted on a 1–15 scale
(1 = criterion k does not contribute to value; 15 = criterion
is the most important one for value). Then, based on the as-
sessment included in the MIF, each member of the TTRAM
assigns as EVIDEM a 0–3 point to each criterion that reflects
how significant s/he considers the improvement made by the
new technology. The individual points are then aggregated, and
the regional board finally applies the Multiple Criteria Decision
Analysis (MCDA) to quantify the multidimensional impact of
the novel technology.
The linear addictive model cannot include the six implicit
criteria. These criteria are deemed implicit because no “univer-
sal” score can be assigned to them. Their evaluation is entangled
with an evaluation of the setting of application and moment of
adoption. The criterion “Historical and Political Context” is
illustrative, in this regard, as the consistency of the new tech-
nology with the context depends on where, when and by whom
the appraisal is performed.
Each implicit criterion can add important clues to the over-
all appraisal, but their inclusion in the linear addictive equation
would make the MCDA spurious. The appraisal of implicit cri-
teria is, in fact, “subjective” and contextual while the MCDA
manifests “objective,” evidence-based impacts of the technol-
ogy. Implicit criteria are then elaborated with a qualitative as-
sessment of whether the technology would produce a positive,
negative, or nonsignificant impact.
The appraisal thus results in a quantitative result—that is,
the score for fifteen criteria—and six qualitative evaluations
that the regional policy maker will use to substantiate and le-
gitimize the final decision and to communicate it to the public,
the industry, the providers and any relevant stakeholder.
At the end, all information produced in the assessment and
appraisal stages are made public, that is, (i) the contents of
the MIF, (ii) the scores and comments made by the TTRAM
(properly anonymized), (iii) an executive summary of the final
appraisal decision. Proponents of the new technology are given
the opportunity to appeal against a negative decision.
STATE OF PRACTICE
The application of the VTS framework started at the end of
2011. As we write, almost 2 years passed from its inception and
twenty-six technologies have been signaled: seven diagnostic
devices, eight interventional devices, two vascular procedures,
six categories of drugs, one imaging technology, and two special
food formulations.
Thus far, fourteen proposals were rejected at step 1 (prior-
itization) because their effectiveness could not be sufficiently
documented or was judged inferior to available alternatives,
while two proposals are currently awaiting prioritization. Nine
of the remaining ten proposals have been admitted to step 2
(full assessment): three assessments proceeded to step 3 (ap-
praisal, one finished and two ongoing) while six assessments
are ongoing. Another proposal was judged clearly superior to
alternatives at priority phase and proceeded directly to quick
appraisal, which ended positively.
At present stage, no relevant issue has emerged in neither the
prioritization stage, for instance, priority rejections have been
accepted as legitimate, nor the assessment stage, for instance,
the groups of experts are working steadily in data collection,
issue assessment, and criteria weighting.
DISCUSSION
Regione Lombardia (RL) sought to institutionalize HTA meth-
ods and pragmatics through: (i) high standardization of activ-
ities, actors, criteria involved in the process; (ii) reliance on
normative regulation to compel actors into performing VTS
standards; (iii) central role assigned to scientific evidence.
RL had to deliver a framework that was both an effec-
tive decision-support system and a powerful agent of change
in stakeholders’ behaviors. Facing stakeholders that were re-
luctant, unaccustomed, or unaware of HTA (16), RL designed
interventions—for example, the mobilization of regulatory sup-
port, conferring status to NVPCI and TTRAM—to legitimize
HTA as a new routine.
In this regard, a crucial intervention was the application
of the EUnetHTA Core Model in a normative process that in-
cludes prioritization, assessment, and appraisal of requests. The
operationalization of the Core Model occurred through (i) a
full adoption of its issues and topics for data collection and
impact assessment and (ii) the inclusion of EVIDEM criteria
and MCDA for the appraisal of requests. The integration be-
tween EUnetHTA and EVIDEM models is unproblematic, as
the former provides elements for collecting data and assessing
impacts while the latter instruments for supporting decisions.
Moreover, the integration ensured the implementation of the
Core Model in RL, at the expense of a few changes such as
the redefinition of EUnetHTA domains in dimensions and the
repositioning of topics and issues in a different, goal-oriented,
structure of criteria, and dimensions.
This approach has both strengths and drawbacks. On the
positive side, the standardization and explicit regulation of
the HTA process instill uniformity and transparency in a pro-
cess that may be highly elusive. While subjectivity cannot be
completely removed, the framework seeks to minimize discre-
tion in decision making and to produce decisions perceived as
legitimate by the stakeholders. The adoption of EUnetHTA and
EVIDEM models, the commitment to systematic reviews and
the reliance on field experts all manifest an intention to legit-
imize a rigorous decision making. On the negative side, the
VTS framework unfolds a complex process whose standards
and requirements might limit flexibility, adaptability, and time-
liness. Time is, at present, the key issue under consideration. The
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process now lasts 6/8 months from prioritization to the final ap-
praisal and significant time containments have been achieved by
a recent introduction of a Web-platform that allows members to
collaborate on remote without frequently meeting face-to-face;
and by focusing on technologies which already have advanced
evidence bases. RL is presently seeking to move a step fur-
ther and couple situations in which RL needs to perform the
whole process of prioritization, assessment and appraisal (act-
ing as “HTA-Doer”) with others in which it can use pre-existing
assessments and focus only on the appraisal of results (thus
acting as “HTA User”). The use of external assessments (prop-
erly validated and adapted) thus represents the second stage in
the institutional change of HTA for RL—with the expectation
of ramping-up the production of evidence-based decisions to a
steady high level.
CONCLUSIONS
The VTS framework was designed in RL as an application of
the EUnetHTACoreModel to inform investment/disinvestment
decisions. The Core Model is adopted unabridged in the topics
and issues that are meant for data collection and technology
assessment. The VTS framework provides however changes in
those components – dimensions and criteria—that are meant for
prioritization and appraisal. These changes move in addition to,
not in substitution of, the Core Model. They serve the purpose,
in fact, to address those areas that are not explicitly covered by
EUnetHTA and allow the direct use of the Core Model also for
decision making. Changes leave unaltered the core aspects of
the model, such as breaking down the assessment into small,
standardized and replicable units, the nature of collected data
and the process of full assessment.
The adoption of EUnetHTA issues into a structure of cri-
teria can suggest that the Core Model can be used not just for
assessment purposes, but also to support directly the appraisal.
The VTS framework hints to a promising implementation of the
EUnetHTA assessment tools with the EVIDEM multiple crite-
ria appraisal methods, without compromising their respective
objectives and approaches.
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